Hepion Pharmaceuticals Files 8-K/A Amendment
Ticker: CTRVP · Form: 8-K/A · Filed: Apr 4, 2025 · CIK: 1583771
| Field | Detail |
|---|---|
| Company | Hepion Pharmaceuticals, Inc. (CTRVP) |
| Form Type | 8-K/A |
| Filed Date | Apr 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements
Related Tickers: HEPA
TL;DR
Hepion Pharma (HEPA) filed an 8-K/A amendment for March 4th financials. Check for updates.
AI Summary
Hepion Pharmaceuticals, Inc. filed an 8-K/A on April 4, 2025, to amend a previous filing. The amendment pertains to the financial statements and exhibits related to the period ending March 4, 2025. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name on August 6, 2013.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to the company's disclosures. Investors should review the amended information for any material changes.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, not indicating new material events or financial distress.
Key Players & Entities
- Hepion Pharmaceuticals, Inc. (company) — Registrant
- ContraVir Pharmaceuticals, Inc. (company) — Former company name
- March 4, 2025 (date) — Period of report
- April 4, 2025 (date) — Filing date
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previous report, specifically concerning the financial statements and exhibits for the period ending March 4, 2025.
When was the original event reported that this 8-K/A amends?
The earliest event reported in this filing was on March 4, 2025.
What was Hepion Pharmaceuticals, Inc. formerly known as?
Hepion Pharmaceuticals, Inc. was formerly known as ContraVir Pharmaceuticals, Inc.
When did the company change its name?
The company changed its name from ContraVir Pharmaceuticals, Inc. to Hepion Pharmaceuticals, Inc. on August 6, 2013.
What is the principal executive office address for Hepion Pharmaceuticals, Inc.?
The address of the principal executive offices is 55 Madison Ave., Suite 400-PMB# 4362, Morristown, NJ 07960.
Filing Details
This Form 8-K/A (Form 8-K/A) was filed with the SEC on April 4, 2025 regarding Hepion Pharmaceuticals, Inc. (CTRVP).